Patent · US Active

TACI binding molecules

US12337035B2 · kind B2 · utility

0Cited by

0References

24Claims

0Family size

Assignee

Kite Pharma, Inc. · US

Inventors

Jonathan Belk · Lebanon, US
Eugene Bolotin · Berkeley, US
Raghavender Chivukula · Hayward, US
Matthew Drever · Concord, US
Edward H. Liao · Petaluma, US

Key dates

Filing date	Mar 25, 2022
Grant date	Jun 24, 2025
Priority date	—
Expiry date	Jun 2, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the dual TACI-BCMA binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.